Su, Yichi http://orcid.org/0000-0001-5715-835X
Walker, Joel R.
Park, Yunhee
Smith, Thomas P.
Liu, Lan Xiang
Hall, Mary P.
Labanieh, Louai
Hurst, Robin
Wang, David C.
Encell, Lance P.
Kim, Namdoo http://orcid.org/0000-0002-8584-1823
Zhang, Feijie
Kay, Mark A. http://orcid.org/0000-0002-2799-2615
Casey, Kerriann M. http://orcid.org/0000-0003-4228-928X
Majzner, Robbie G.
Cochran, Jennifer R.
Mackall, Crystal L.
Kirkland, Thomas A. http://orcid.org/0000-0003-0859-5785
Lin, Michael Z. http://orcid.org/0000-0002-0492-1961
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (1R21DA048252)
American Heart Association (15IRG23290018)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P5P30CA124435)
Article History
Received: 18 March 2019
Accepted: 8 June 2020
First Online: 13 July 2020
Competing interests
: J.R.W., T.P.S., M.P.H., R.H., L.P.E. and T.A.K. are employees of Promega Corporation and inventors on a patent describing furimazine and furimazine derivatives. L.L. is a consultant for Lyell Immunopharma. R.G.M. is a consultant for Lyell Immunopharma, Xyphos Biosciences, Gamma Delta Therapeutics and Illumina Radiopharmaceuticals. Y.P., D.C.W., L.X.L., Y.S., N.K., K.M.C. and M.Z.L. declare no competing interests. C.L.M. is a founder, holds equity in and is a consultant for Lyell Immunopharma, consults for Neoimmune Tech, Apricity and Nektar, holds equity in Apricity and Allogene and has received royalties from NIH for a CD22-CAR licensed to Juno.